Introduction
============

A major challenge in neurodegenerative disease research is to identify disease-modifying strategies. Given the complexity of sporadic disease such as Alzheimer's disease (AD) or Parkinson's disease (PD), the study of inherited neurodegenerative disease is expected to shed light on the mechanisms that underlie neurodegeneration. In this respect, Huntington's disease (HD), a dominantly inherited disease with CAG expansion in the huntingtin (htt) gene and expanded polyglutamine (polyQ) tracts in the htt protein causing striatal and cortical degeneration (Walker, [@B88]) has become a "model neurodegenerative disease." The large number of models for HD, the knowledge on HD mechanisms (Zuccato et al., [@B97]) and the availability of well-characterized cohorts of HD subjects indeed provide a unique framework in which to investigate the therapeutic potential of target genes and pathways. Among the many genes that could be targeted in HD (Zuccato et al., [@B97]), longevity modulators, and more largely, genes which are essential to cellular homeostasis are the subject of intense research because they may directly regulate important cell survival mechanisms such as for example oxidative stress response and protein quality control. While several genes may modulate lifespan (Narasimhan et al., [@B62]), a limited number of genes may function to promote longevity. This is notably true for the FOXO proteins, a family of forkhead transcription factors that is conserved from *Caenorhabditis Elegans* (*C. elegans*) to mammals. FOXO factors indeed increase longevity in invertebrates, and in mammals they have a wide range of functions as further detailed below. The purpose of this review is to discuss the role of FOXO proteins and members of the FOXO network as neurodegeneration modulators.

The FOXO Network
================

Several signaling pathways such as the PI3K--AKT pathway, stress-activated pathways such as the MST-1 and JNK pathways, and the SIR-2 and AMPK pathways converge onto FOXO proteins to regulate a variety of biological processes which are important to development, metabolism, tumor suppression, and longevity (Calnan and Brunet, [@B11]). A large number of studies have indicated that, in response to external stimuli including growth factors such as insulin and insulin-like growth factor (IGF-1), nutrients, cytokines, and oxidative stress stimuli, these pathways are able to regulate the subcellular localization, DNA binding activity, transcriptional activity, and stability of these FOXO proteins. These studies have been thoroughly reviewed in excellent articles to which to refer for more details (Greer and Brunet, [@B30]; Calnan and Brunet, [@B11]; Landis and Murphy, [@B48]; Yen et al., [@B93]); a finely tuned regulatory network is emphasized in which, through a series of context-dependent post-translational modifications and interactions with co-regulators, FOXO proteins are able to integrate several types of external stimuli to regulate gene expression and modulate cell cycle arrest, apoptosis, autophagy, angiogenesis, differentiation, stress resistance, stem cell maintenance, glucogenesis, and food intake. Nutrient-sensing pathways are important upstream components of this regulatory network. Nutrient-sensing factors such as insulin/insulin-like growth factor (IGF) signaling (IIS), NAD+-dependent histone deacetylases (sirtuins/SIR-2/SIRTs), the target of rapamycin (TOR) kinase, and ribosomal S6 Kinase (TOR/S6K) pathway and the AMPK pathway may be targeted by dietary restriction to slow aging (Cabreiro and Gems, [@B10]; Chiacchiera and Simone, [@B16]). Additionally, nutrient-sensing pathways are also key regulators of FOXO activity. It is for example well-established that IIS modifies FOXO proteins at specific phosphorylation sites, with reduction of IIS activating FOXO, which may translate into lifespan extension in invertebrates (Calnan and Brunet, [@B11]). Besides IIS and modulation of FOXO phosphorylation, the SIRT1 nutrient-sensing pathway and modulation of FOXO acetylation is another important FOXO regulator. Increased *sir-2.1*/SIRT1 dosage in high-copy *sir-2.1* transgene containing strains was indeed found to strongly increase lifespan in *C. elegans*, an effect that requires *daf-16*/FOXO (Tissenbaum and Guarente, [@B85]), suggesting that sirtuins could play important roles in lifespan extension. This notion has been recently challenged by additional studies in *C. elegans* and *Drosophila melanogaster* (Burnett et al., [@B9]; Rizki et al., [@B77]). These studies revealed that lifespan extension may be partially attributable to background mutations producing a dye-filling defective ("Dyf") phenotype in high-copy *sir-2.1* overexpressor strains (Burnett et al., [@B9]; Rizki et al., [@B77]). While this raised the possibility that sirtuins might not be longevity-promoting factors to that extent, two independent studies indicated that lifespan extension (10--15%) may also be achieved in low-copy *sir-2.1* overexpressor strains (Rizki et al., [@B77]; Viswanathan and Guarente, [@B87]). Importantly, one of theses studies (Rizki et al., [@B77]) was consistent with the notion that *sir-2.1* interacts with *daf-16*/FOXO and its co-factors such as 14-3-3 proteins in modulating lifespan (Berdichevsky et al., [@B6]). Furthermore, background mutations were not responsible for the strong level of neuroprotection achieved against mutant polyQs by *sir-2.1* overexpression (Burnett et al., [@B9]). Thus, while additional investigation will be needed to determine to which extent sirtuins may promote lifespan extension, sirtuins stand as important longevity factors that are relevant to neuronal protection in neurodegenerative disease and other protective effects in metabolic disease (Kim et al., [@B44]; Baur et al., [@B4]; Burgess, [@B8]; Jeong et al., [@B40]; Jiang et al., [@B41]). One may wonder why mutations producing a Dyf phenotype were found in *sir-2.1* overexpressor strains despite the care made by the *C. elegans* community with distributing mutants after multiple outcrosses. The answer might come from studies made with the search for mutants resistant to avermectin (Rand and Johnson, [@B74]), an antiparasitic drug. Many low-level ivermectin resistance mutations in *che*, *osm*, and *dyf* genes may produce defects in the amphid sensilla, low-level ivermectin resistance is common in *C. elegans* (1 in 5000 eggs in the absence of mutagenesis) and the ivermectin resistance allele frequency in wild nematode populations may be as high as 1% (C. D. Johnson, personal communication). Additionally, mutations that cause defects in sensory cilia genes may also extend longevity (Apfeld and Kenyon, [@B2]). The *dyf* mutations may thus occur at relatively high rates, which calls for the regular assessment of *C. elegans* mutants for dye-filling defects in studies of longevity.

In addition to be regulated by kinases and deacetylases, FOXO activity is regulated by ubiquitin complex members such as Skp2, a protein that promotes FOXO1 degradation (Huang et al., [@B37]), and by co-factors such as β-catenin, a protein that binds to FOXO3a and regulates its transcriptional activity in response to oxidative stress (Essers et al., [@B26]). The FOXO proteins may compete with the canonical Wnt effector T cell factor (TCF) for binding to β-catenin (Hoogeboom et al., [@B35]), which further highlighted the importance of β-catenin in the regulation of FOXO activity. While FOXO proteins may act together with other transcription factors to regulate gene expression (Landis and Murphy, [@B48]), they stand at the center of a large network of upstream regulators, co-factors, and downstream targets (Figure [1](#F1){ref-type="fig"}) which are important for cell homeostasis. Interestingly, studies based on chromatin immunoprecipitation (Oh et al., [@B63]; Schuster et al., [@B79]), gene expression profiling in *C. elegans* (McElwee et al., [@B57]; Murphy et al., [@B61]) and mouse neural stem cells (NSCs; Paik et al., [@B66]; Renault et al., [@B75]), and other approaches (Lee et al., [@B49]; Yu et al., [@B94]) highlighted thousands of putative FOXO-regulated genes (Jensen et al., [@B39]; Murphy, [@B60]). These results open the avenue to a better understanding of FOXO activity in regulating downstream mechanisms in specific contexts. Given that FOXO proteins act in specific cells and tissues to execute different outputs (Landis and Murphy, [@B48]), it is anticipated that specific transcriptional targets may be engaged into different FOXO-mediated responses. Gene expression studies performed in either *C. elegans* nematodes (McElwee et al., [@B57]; Murphy et al., [@B61]) or mouse NSCs (Lee et al., [@B49]; Yu et al., [@B94]) emphasized a small number of FOXO-regulated genes across species and biological conditions (Table [1](#T1){ref-type="table"}). Although poor overlap may be partially attributable to differences in the species and/or methods used for gene expression profiling, these studies suggest that FOXO proteins indeed regulate specific targets in different contexts. In addition to being important for stem cell homeostasis and adult longevity, FOXO factors are involved in development and cell differentiation (Kitamura et al., [@B45]; Demontis and Perrimon, [@B23]; Yuan et al., [@B95]; de la Torre-Ubieta et al., [@B22]; Kerdiles et al., [@B43]; Schuff et al., [@B78]), and they may be important to promote adult neurogenesis as suggested by studies in *Drosophila* *melanogaster* (Siegrist et al., [@B80]). Thus, FOXO factors may be essential to cell response homeostasis during the entire lifetime of a living organism. As such, it is not surprising that FOXO proteins and their main regulators such as sirtuins were implicated in the protection against age-associated diseases such as cancer, diabetes, cardiovascular disease, and neurodegeneration (Dansen and Burgering, [@B20]; Chiacchiera and Simone, [@B16]; Herranz and Serrano, [@B34]).

###### 

**Putative FOXO targets emphasized by microarray analysis in either *C. elegans* or mouse NSCs, or both**.

  Mouse gene name         Worm ORF ID                            *C. elegans*   Mouse NSCs          
  ----------------------- -------------------------------------- -------------- -------------- ---- ----
  Cav1                    T13F2.8                                U              --             D    --
  Mxd1                    R03E9.1                                D              --             D    D
  Sod2                    C08A9.1                                D              U              --   --
  Crisp                   F49E11.9, H10D18.2, ZK384.1, ZK384.2   D              U (F49E11.9)   --   --
  RIKEN cDNA 6230409E13   C54D10.1                               D              U              --   --
  Nxnl2                   F17B5.1                                D              U              --   --
  Dgat2                   K07B1.4                                D              U              --   --
  Birc5                   C50B8.2                                --             U              --   U
  Myo1b                   F29D10.4                               --             U              --   U
  Slc25a5                 W02D3.6                                --             U              --   U
  B3galt1                 E03H4.11                               U              --             --   U
  Chrna7                  R02E12.8                               U              --             --   U
  Gmeb1                   C44F1.2                                U              --             --   U
  Gspt1                   H19N07.1                               U              --             --   U
  Jag1                    R107.8                                 U              --             --   U
  Lta4h                   ZC416.6                                U              --             --   U
  Mapk8                   B0478.1                                U              --             --   U
  Pcna                    W03D2.4                                U              --             --   U
  Psmc5                   Y49E10.1                               U              --             --   U
  Bphl                    K01A2.5                                U              --             --   D
  Dpyd                    C25F6.3                                U              --             --   D
  Slc15a2                 K04E7.2                                U              --             --   D
  Comtd1                  Y40B10A.2, Y40B10A.6                   D              --             --   U
  Gnb5                    F52A8.2                                D              --             --   U
  Icmt                    F21F3.3                                D              --             --   U
  Rexo1                   Y56A3A.33                              D              --             --   U
  Abhd4                   C37H5.2                                D              --             --   D
  Acsl3                   C46F4.2                                D              --             --   D
  Alkbh4                  F09F7.7                                D              --             --   D
  Cat                     Y54G11A.6                              D              --             --   D
  Cyb5                    W02D3.1                                D              --             --   D
  Fads2                   W08D2.4                                D              --             --   D
  Ppap2c                  T28D9.3                                D              --             --   D
  Syt11                   T23H2.2                                D              --             --   D

*U, up-regulated; D, down-regulated. \*The promoter of these dysregulated genes also contain FOXO binding sites (McElwee et al., [@B57]). --, Not dysregulated*.

*This table is based on the simple comparison of four studies performed in either *C. elegans* (McElwee et al., [@B57]; Murphy et al., [@B61]) or mouse NSCs (Lee et al., [@B49]; Yu et al., [@B94])*.

![**Simplified view of the FOXO network**. This diagram shows signaling pathways well-established (straight arrows) or hypothesized (dashed arrow) to converge onto FOXO. The list of target gene classes and physiological outputs is not exhaustive.](fphar-03-00015-g001){#F1}

The SIR-2/FOXO Pathway and Its Role in Degenerative Disease
===========================================================

For the same reason that pathways converging onto FOXO are important to cell survival and longevity, they are of particular interest to explore how to promote neuron or muscle cell survival in degenerative disease. Over the past years, accumulating evidence on the therapeutic potential of FOXO and its interactors for age-related diseases has been obtained. Perhaps the first observation suggesting that longevity-promoting factors might be able to modulate the toxicity of degenerative disease proteins was obtained in the nematode *C. elegans*. In transgenic nematodes expressing polyQ tracts in body wall muscle cells, reducing IIS by use of *age-1*/PI3K loss-of-function (LOF) mutants decreased the toxicity associated to expanded polyQs, and this effect was dependent on *daf-16*/FOXO (Morley et al., [@B59]). Direct evidence for longevity-promoting factors such as SIR-2 and FOXO to protect diseased neurons at an early stage of cellular decline was obtained by using a *C. elegans* model of HD pathogenesis in which expression of polyQ-expanded N-terminal huntingtin in touch receptor neurons induced neuronal dysfunction (lossglu of response to light touch) in the absence of cell death (Parker et al., [@B69]). In these animals, increased *sir-2.1*/SIRT1 dosage protects from expanded polyQs, with reduction of axonal dystrophy, whereas *sir-2.1* LOF aggravates expanded polyQ toxicity (Parker et al., [@B68]). This neuroprotective effect is not due to unrelated mutations (i.e., mutations producing a Dyf phenotype) in the high-copy *sir-2.1* transgene containing strains as neuroprotection was observed to the same extent in non-Dyf, *sir-2.1* overexpressors (Burnett et al., [@B9]). Additionally, *sir-2.1* neuroprotection in this model requires *daf-16*/FOXO (Parker et al., [@B68]), emphasizing a role for the SIR-2.1/DAF-16 pathway. This suggested that raising the activity of the SIRT1 pathway may protect from mutant huntingtin in mammalian models of HD. This notion was supported by other *C. elegans*-based studies (Bates et al., [@B3]), and consistent with the protective effects of situins in common neurological disorders. However, studies in *Drosophila* *melanogaster* suggested that Sir-2 knockdown protects from neurodegeneration as induced by N-terminal htt expression in the compound eye, with no effect of overexpressing Sir-2 (Pallos et al., [@B67]). These results suggested that the role of Sir-2 in mutant polyglutamine neurons may be complex. Nematodes with expanded polyQ expression in touch receptor neurons recapitulate neuron dysfunction before cell death and pointed to the FOXO-dependent effect of homozygous loss of Sir-2 (Parker et al., [@B68]). Flies with expanded polyQ expression in the eye show neurodegeneration and pointed to an effect of heterozygous loss of Sir-2 that may be unrelated to longevity (Pallos et al., [@B67]). While these differences illustrated the importance of parameters such as the severity of pathology, type of gene dosage and identity of downstream effectors when pursuing therapeutic targets, two independent studies recently reported that SIRT1 is neuroprotective in several mouse models of HD (Jeong et al., [@B40];Jiang et al., [@B41]). Interestingly, FOXO3a may be involved in the neuroprotective effects of SIRT1 and the reduction of SIRT1 exacerbates mutant huntingtin toxicity (Jiang et al., [@B41]), which should help settle the question. Besides SIRT1 manipulation, SIRT2 inhibition may also be neuroprotective in diseases such as HD (Luthi-Carter et al., [@B53]) and PD (Outeiro et al., [@B64]). As suggested by the function of SIRT2, a microtubule deacetylase, and by the effects of SIRT2 inhibitors in models of HD (Luthi-Carter et al., [@B53]), the mechanisms for neuroprotection by SIRT2 inhibition may differ from those elicited by SIRT1 manipulation. However, FOXO proteins are deacetylated by SIRT2 (Zhao et al., [@B96]; Wang et al., [@B89]), raising the possibility that neuroprotection by SIRT2 inhibition might involve FOXO activity.

Consistent with the protection of mutant polyQ neurons by SIR-2/SIRT1, neuroprotection by *sir-2.1* overexpression was also demonstrated in *C. elegans* nematodes expressing octa-repeat expanded PrP in mechanosensory neurons (Bizat et al., [@B7]). In these animals, the neuroprotective effect of *sir-2.1* was unrelated to an effect on the conformation of mutant PrP since *sir-2.1* overexpression did not reduce proteinase K-resistant PrP levels (Bizat et al., [@B7]). Several studies have further extended the neuroprotective activity of SIR-2/SIRT1 and FOXO in models of neurodegenerative diseases. Sirtuin SIRT1 is up-regulated in mouse models of AD and amyotrophic lateral sclerosis (ALS), and SIRT1 is protective in cell-based models of ALS and AD/tauopathies (Kim et al., [@B44]), providing evidence for SIRT1 to protect diseased neurons. Neurite outgrowth, cell viability and tolerance to degeneration induced by Aβ(1--42) oligomers are promoted in primary neurons from mice with neuron-specific SIRT1 overexpression (Guo et al., [@B32]), further supporting the notion that SIRT1 is able to protect diseased neurons. In *C. elegans* nematodes expressing Aβ(1--42) in body wall muscle cells (Link et al., [@B52]), *daf-16*/FOXO and heat shock factor 1 (*hsf-1*) cooperate to regulate a two-step cell survival response involving disaggregation/aggregation (Cohen et al., [@B17]). Consistently, in a mouse model of AD (APPswe/Presenilin1-ΔE9 mice), genetically reducing IGF signaling protects from Alzheimer's-like disease symptoms (Cohen et al., [@B18]). Finally, it is notable that allelic variation in FOXO3A was associated with the ability to be long-lived as suggested by several association studies in populations of centenarians (Willcox et al., [@B91]; Anselmi et al., [@B1]; Flachsbart et al., [@B27]; Li et al., [@B50]; Soerensen et al., [@B82]; Kleindorp et al., [@B46]).

While the SIR-2.1/DAF-16 pathway may protect mutant polyQ neurons, it has opposite effects in a *C. elegans* model of oculopharyngeal muscular dystrophy (OPMD), a late-onset disease caused by expanded polyalanines in the PABPN1 protein (Catoire et al., [@B12]). In *C. elegans* transgenics expressing human PABPN1 in body wall muscle cells, *sir-2.1* overexpression indeed aggravates muscle cell decline and abnormal motility caused by mutant PABPN1 expression, whereas *sir-2.1* LOF is protective in a *daf-16*/FOXO-dependent manner (Catoire et al., [@B12]). These observations suggested that the status of FOXO activity in mutant polyQ neurons is different from that of mutant polyAla muscle cells. These results also suggested that SIRT1 inhibitors have therapeutic potential in OPMD as further illustrated by pharmacological studies in PABPN1 nematodes (Pasco et al., [@B70]).

Modulation of Neurodegenerative Disease Targets in the FOXO Network
===================================================================

Over the past years, studies of SIRT1/FOXO activity in models of disease have the search for SIRT1 activators and inhibitors with clinical potential. While the aim of this review is not to cover drug discovery and clinical development in the field of sirtuin research, it is notable that the mechanisms of action of SIRT1-activating compounds (STACs) have been the subject of debate. This applies to resveratrol, a plant polyphenol that has a broad range of beneficial activities on health span (Wood et al., [@B92]; Baur et al., [@B5]; Fulda and Debatin, [@B29]; Lagouge et al., [@B47]), is neuroprotective in several models of neurodegenerative diseases (Parker et al., [@B68]; Kim et al., [@B44]; Bizat et al., [@B7]; Richard et al., [@B76]) and has attracted a lot of attention as a potential drug (Patel et al., [@B71]). Resveratrol was initially thought to primarily activate SIRT1 (Howitz et al., [@B36]). It is now thought that resveratrol has multiple mechanisms of action (Harikumar and Aggarwal, [@B33]). Resveratrol might not always require SIRT1 for activity against expanded polyQs (Parker et al., [@B68]; Pallos et al., [@B67]), and it could activate AMPK (Dasgupta and Milbrandt, [@B21]) and the peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha; Lagouge et al., [@B47]) and inhibits PI3K (Frojdo et al., [@B28]). This promoted the search for selective SIRT1 activators (Milne et al., [@B58]), which led to find that they may act as caloric restriction mimetics (Smith et al., [@B81]). Although STACs hold promises for the treatment of age-associated diseases, their mechanisms of action and therapeutic potential was controversial. A positive aspect of this controversy was to emphasize the need for more robust acetylation assays and in-depth assessment of the promiscuity of STACs. Studies in the field indeed raised the possibility that complex formation between STACs and fluorophore-labeled substrate peptides plays a role in the activation of SIRT1 (Pacholec et al., [@B65]), whereas other studies subsequently showed that STACs are able to activate unlabelled peptides, suggesting that STACs may interact directly with SIRT1 and activate SIRT1-catalyzed deacetylation through an allosteric mechanism (Dai et al., [@B19]). While the debate regarding STAC activities might continue, progress appears to be made with harnessing the therapeutical potential of STACs in metabolic disorder. The development of SRT501 (a formulation of resveratrol) for diabetes was terminated whereas new STACs structurally distinct from resveratrol such as SRT2104 are being evaluated (Huber and Superti-Furga, [@B38]). Further developments are highly awaited to know if these molecules may provide clinically safe drugs for neurodegenerative disease. The situation has been less controversial in regard to sirtuin inhibition as SIRT inhibitors with good selectivity for either SIRT1 (e.g., EX-527) or SIRT2 (e.g., AGK2) have been identified (Mai et al., [@B55]; Luthi-Carter et al., [@B53]; Pasco et al., [@B70]; Taylor et al., [@B84]). Compared to the mechanisms for neuroprotection by SIRT1 activation, the biology of neuroprotection by SIRT inhibition is not understood to that extent. In any case, progress with identifying the neuronal function of sirtuins (Dietrich et al., [@B24]; Ramadori et al., [@B73], [@B72]; Guo et al., [@B32]; Maxwell et al., [@B56]) and targets modulated by these enzymes (Wang et al., [@B90], [@B89]; Li et al., [@B51]; Zhao et al., [@B96]) will help define the therapeutic potential of SIRT inhibitors in neurodegenerative disease.

Besides sirtuins, another neurodegenerative disease target of interest in the FOXO network is AMPK, a key regulator of cellular metabolism that is activated by a decrease in energy levels (Steinberg and Kemp, [@B83]). Interestingly, an AMPK--FOXO3a pathway might be involved in shifting the cell from energy consumption to energy production in cancer-specific metabolism (Chiacchiera and Simone, [@B15], [@B16]; Chiacchiera et al., [@B14]), a mechanism also emphasized by the ability of an AMPK--FOXO pathway to mediate longevity in response to dietary restriction in *C. elegans* (Greer et al., [@B31]). Since there is multiple evidence for mitochondrial and metabolic defects in neurodegenerative diseases such as HD (Zuccato et al., [@B97]), it is tempting to speculate that one important mechanism to compensate for metabolic defect in HD could be the use of an AMPK--FOXO pathway. If true, then AMPK activation might protect against the early phases of the pathogenic process in neurodegenerative disease. However, the AMPK--FOXO pathway may end up activating autophagic cell death upon prolonged metabolic stress in cancer cells (Chiacchiera and Simone, [@B15], [@B16]; Chiacchiera et al., [@B14]), raising the possibility that AMPK--FOXO might contribute to neurodegeneration, which might be particularly harmful during the late phases of the pathogenic process in neurodegenerative disease. Studies in models of neurodegeneration reflect the complexity of the AMPK-mediated regulation of cell survival. Although the AMPK activator metformin protects primary cortical neurons from etoposide-induced cell death (El-Mir et al., [@B25]) and ameliorates survival and motor defects in R6/2 transgenic mice expressing mutant N-terminal huntingtin (Ma et al., [@B54]), other studies suggested that metformin may increase the generation of Aβ peptides via BACE1 upregulation in cellular models (Chen et al., [@B13]). In regard to AMPK activity in neurons, conflicting observations have been made. Because neurons do not efficiently store nutrients, AMPK may be essential to neuron activity and survival, suggesting that AMPK activation might protect neurons from metabolic stress in neurodegenerative disease. However, AMPK appears to be abnormally activated in pre-tangle and tangle neurons in AD and other tauopathies (Vingtdeux et al., [@B86]). Additionally, there is nuclear translocation of the AMPK-alpha1 subunit in the striatum of post-mortem HD brains and mice with a fast-developing HD pathology (Ju et al., [@B42]). While this suggests that AMPK might have a pathological role in HD, studies of AMPK in additional models of HD are warranted considering the pro-survival role of AMPK in neurons and diversity of pathology in HD mice. Collectively, these data highlight the need for more studies of the modulation of AMPK activity toward specific targets in models that recapitulate the early/mild versus late/severe components of the pathogenic process in neurodegenerative disease. This will allow the potential of AMPK-targeted therapy in neurodegenerative disease treatment to be clarified. It will also be important to identify the small compound molecules that might be used in this respect (Steinberg and Kemp, [@B83]).

Perspectives
============

There is accumulating evidence on the protective role of FOXO proteins and their interactors in response to cellular stress in age-related diseases. One of the current challenges is to identify the downstream mechanisms by which FOXO factors are essential to neuron survival in neurodegenerative disease. Given the complex regulation of gene expression by FOXO proteins and their interactors, it will be important to investigate how FOXO transcriptional targets may be involved in the regulation of survival responses in specific neurodegenerative diseases and to evaluate whether this may be relevant to other neurodegenerative diseases. Another challenge is to assess whether the pathways that regulate FOXO transcriptional activity should be activated or inhibited to modify the pathogenic process in neurodegenerative disease, and whether the same approach should be used against the early/mild versus late/severe phases of the pathology. Sustaining neuron survival at an early phase of the pathology and reducing neuronal cell death in late disease might require the same FOXO activity to be modulated in opposing fashions. This possibility is supported by the ability of FOXO proteins and their interactors to orchestrate two-step responses in which the net outcome may be cell survival (Cohen et al., [@B17]) or cell demise (Chiacchiera and Simone, [@B16]) in response to prolonged stress. Thus, while several questions remain unanswered, future and exciting developments are expected to shed light on the importance and therapeutic potential of the FOXO network in neurodegenerative disease.
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